SCHEMBL8280002

SCHEMBL8280002

CCNCc1nc2c(OC)c(Cl)cc(Cl)c2c(=O)[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.50
GAA P10253 1/20 0.50
PIM1 P11309 3/20 0.36
PDE10A Q9Y233 1/20 0.34
PIM2 Q9P1W9 1/20 0.34
CCNE2 O96020 6/20 0.34
CCNE1 P24864 6/20 0.34
CDK2 P24941 6/20 0.34
CDK4 P11802 5/20 0.33
CCND1 P24385 5/20 0.33
CCNB2 O95067 3/20 0.33
CDK1 P06493 3/20 0.33
CCNB1 P14635 3/20 0.33
CCNB3 Q8WWL7 3/20 0.33
PDCD1LG2 Q9BQ51 1/20 0.33
CD274 Q9NZQ7 1/20 0.33
CACNA1G O43497 1/20 0.33
HTR1A P08908 1/20 0.33
HTR1D P28221 1/20 0.33
HTR1B P28222 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8279997 0.91 KDM4E (0.40) KDM4EGAAPIM1PDE10APIM2
SCHEMBL12055986 0.86 CCNE2 (0.43) GAAPDE10ACCNE2CCNE1CDK2
SCHEMBL8280198 0.83 RAB9A (0.39) KDM4EPIM1PDE10ACCNE2CCNE1
SCHEMBL8279158 0.82 KDM4E (0.46) KDM4EGAAPIM1PIM2CCNE2
SCHEMBL8279157 0.81 ALDH1A1 (0.44) KDM4EGAAPDE10A
SCHEMBL8279161 0.80 PIM1 (0.45) PIM1PIM2
SCHEMBL31470105 0.75 TLR7 (0.38) KDM4EGAAPDCD1LG2CD274HTR1A
SCHEMBL18175717 0.69 PIM1 (0.46) PIM1PIM2CCNE2CCNE1CDK2
SCHEMBL12055985 0.67 CCNE2 (0.45) GAACCNE2CCNE1CDK2CDK4
SCHEMBL4061814 0.66 PARP1 (0.44) PIM1PIM2CCNE2CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084459-B2 8-hydroxy-3H-quinazolin-4-(thi)one derivatives; ability to enter CNS, sequester transition metals Cu, Zn and Fe from various amiloid beta entities, reducing their toxicity; neurodegenerative disorders; Alzheimer's, Parkinson's, Cruetzfeldt-Jacob diseases, amyotrophic lateral sclerosis, cataract PRANA BIOTECHNOLOGY LTD (AU) 2011-12-27 US disclosed
US-8084459-B2 8-hydroxy-3H-quinazolin-4-(thi)one derivatives; ability to enter CNS, sequester transition metals Cu, Zn and Fe from various amiloid beta entities, reducing their toxicity; neurodegenerative disorders; Alzheimer's, Parkinson's, Cruetzfeldt-Jacob diseases, amyotrophic lateral sclerosis, cataract PRANA BIOTECHNOLOGY LTD (AU) 2011-12-27 US disclosed
US-20080119470-A1 Neurologically-Active Compounds XOMA TECHNOLOGY LTD. 2008-05-22 US disclosed
US-20080119470-A1 Neurologically-Active Compounds XOMA TECHNOLOGY LTD. 2008-05-22 US disclosed
WO-2005095360-A1 NEUROLOGICALLY-ACTIVE COMPOUNDS PRANA BIOTECHNOLOGY LIMITED (AU) 2005-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119470-A1 Neurologically-Active Compounds ACHE, PSEN1, PSEN2 KDM4E 1854/4885GAA 56/4885PIM1 3819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.